Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Breast 1

Conditions

Carcinoma, Renal Cell 37Parkinson Disease 4, Autosomal Dominant Lewy Body 7Neoplasm Metastasis 4Kidney Neoplasms 4Carcinoma, Transitional Cell 4Squamous Cell Carcinoma of Head and Neck 3Endometrial Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Thyroid Neoplasms 2Ovarian Neoplasms 2Melanoma 2Clear-cell metastatic renal cell carcinoma 2Brain Neoplasms 2von Hippel-Lindau Disease 1Urologic Neoplasms 1Urinary Bladder Neoplasms 1Thrombocytosis 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Penile Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Myeloproliferative Disorders 1

Interventions

Gemcitabine 9pembrolizumab 7Cisplatin 5enfortumab vedotin 4atezolizumab 4Trastuzumab 4Mitomycin 4Carboplatin 4Sunitinib 3Pemetrexed 3dodecyl maltoside 2cabozantinib 2Water 2Sugammadex 2Standard of Care 2Saline Solution 2Paclitaxel 2Nivolumab 2Neostigmine 2Docetaxel 2Cetuximab 2Bevacizumab 2zidovudine 5'-monophosphate-mannose-albumin conjugate 1vinflunine 1valrubicin 1tucatinib 1tislelizumab 1testosterone 17 beta-cypionate 1temsirolimus 1relatlimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urologic Neoplasms × lenvatinib × Genitourinary × Clear all
NCT02915172 2017-06-26

Lenvatinib and Capecitabine in Patients With Advanced Malignancies

M.D. Anderson Cancer Center

Phase 1 Withdrawn
BreastGenitourinary

Breast Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡